Can semaglutide help curb heavy drinking? Early trial hints yes
A small randomized trial suggests semaglutide may help reduce heavy drinking in adults with alcohol use disorder and obesity. The results are encouraging, but they are early and do not change standard treatment yet.
A small randomized trial suggests semaglutide may help people with alcohol use disorder and obesity drink less, especially on heavy-drinking days. The findings are encouraging, but they are early and do not make semaglutide a standard treatment for alcohol problems.
The study was not a replacement for counseling: everyone in the trial also received cognitive behavioral therapy, or CBT. That matters because the results reflect semaglutide plus therapy, not the drug alone.
What researchers studied
According to the National Institutes of Health, the trial enrolled 108 people with alcohol use disorder and obesity. Participants received either semaglutide or placebo once a week for 26 weeks, and all were offered CBT sessions for alcohol use disorder.
The NIH summary says 88 people completed the trial. The study was published in The Lancet and was a randomized, placebo-controlled trial — the kind of design researchers use to test whether a treatment performs better than an inactive comparison.
What changed
Heavy drinking days went down in both groups over time, but the decrease was larger in the semaglutide group. The semaglutide group also had larger drops in total monthly alcohol use, drinks per drinking day, self-reported craving, and other measures of harmful drinking, the NIH said.
Researchers also saw larger declines in several blood markers tied to alcohol use and liver damage in the semaglutide group. At the same time, people taking semaglutide lost more weight, waist circumference, body mass index, and average blood sugar — findings that fit the drug’s known effects.
Side effects still matter
The most common side effects were gastrointestinal symptoms such as nausea, constipation, appetite loss, diarrhea, reflux, and abdominal pain. NIH said these were usually mild to moderate and temporary, but they were more common with semaglutide than placebo.
One participant in the semaglutide group had an adverse event that required hospitalization. That does not prove the drug is unsafe overall, but it does show why tolerability and monitoring matter in any future use for alcohol use disorder.
What semaglutide is approved for
In the United States, semaglutide products are approved for type 2 diabetes and/or weight management, depending on the product. FDA and MedlinePlus also list certain approved uses to lower cardiovascular risk, reduce kidney disease risk in some adults with type 2 diabetes, and treat noncirrhotic MASH in some adults.
Alcohol use disorder is not an FDA-approved indication for semaglutide. So this trial is best understood as early research, not a new approved use.
What remains unknown
The biggest limitations are the small sample size and the narrow group studied. The trial included people with obesity, so it is not yet clear whether the results apply to people with alcohol use disorder who do not have obesity.
Larger and longer studies will be needed to see whether semaglutide truly helps reduce drinking in broader groups, how durable the effect is, and how it compares with or adds to existing alcohol use disorder treatments.
What readers can do
If you or someone in your family is struggling with alcohol use, this study does not mean semaglutide should be used on its own for treatment. The practical next step is to talk with a clinician about proven care options, including counseling and FDA-approved medications for alcohol use disorder.
If drinking is causing withdrawal symptoms, repeated blackouts, injuries, vomiting, confusion, or thoughts of self-harm, seek urgent medical help right away.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
